Immunoglobulin A nephropathy (IgAN or IgA nephropathy), also known as Berger’s disease, is a rare autoimmune condition that damages the glomeruli inside the kidneys. Initial treatment of IgAN…
Acute coronary syndrome (ACS)—subtype of coronary artery disease (CAD)—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable…
The hepatocellular carcinoma therapy market is gradually evolving and experiencing substantial growth. While angiogenesis inhibitors, including sorafenib (Bayer / Amgen), Stivarga (Bayer), Lenvima…
Dry eye disease (DED) is a condition characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. For 13 years, AbbVie’s Restasis was…
Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS…
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the location of the obstruction…
Clarivate Epidemiology’s coverage of amyotrophic lateral sclerosis (ALS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder involving significant social, communication, and behavioral challenges. Behavioral and developmental therapies are the…
Major depressive disorder (MDD) is a highly drug-treated condition that uses an array of drug classes, including, but not limited to, selective serotonin reuptake inhibitors (SSRIs), selective…
The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and the long treatment duration. The availability of premium-priced branded agents prescribed…
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and, ultimately, destruction of the interlobular bile ducts; this process is…
Clarivate Epidemiology’s coverage of RAS comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets (the United States, France,…
The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) continues to fragment as newer entrants in established classes such as TG Therapeutics’ Briumvi, Novartis’s Kesimpta,…